JPAG - PAST MEETINGS
Thursday 11th May 2017
The role of MS in impurity profiling
Royal Society of Chemistry, London
In association with the British Mass Spectrometry Society.
Impurities provide no benefit to patients; however, it is pragmatically accepted that complex, multi-stage pharmaceuticals cannot be manufactured without drug substance impurities or that drug products cannot be manufactured and stored without degradation products.
This symposium will explore the role of Mass Spectrometry (MS) in the identification and quantification of the various impurities that can be formed. These include difficult to analyse impurities as well as mutagenic and elemental impurities that are controlled to health based safety limits that are significantly lower than normal ICH Q3A/Q3B impurities.
This symposium should be of interest to development, production, and academic scientists, as well as contract research organisations (CROs).
Registrations starts at 09.30. The symposium starts at 10.00 h and finishes at about 16.30 h.
Dr Claudio Brunelli - Pfizer
Dr Elspeth Gray - MHRA
Dr Sarah James - LGC
Dr Martin Ott - Lhasa
Dr Mark Perkins - Anatune
Dr Andrew Ray - AstraZeneca
Dr Mansoor Saeed - Syngenta
Dr Alec Simpson - GlaxoSmithKline
GET THE REPORT FOR THIS EVENT?RETURN TO MEETINGS
We will send it to you.
WANT TO SEE MORE?PAST MEETINGSSymposium - October 2011
You will have access to materials for meetings that you have attended.
You will need to Sign In to activate access to your additional options.
Once Signed in, click on RESOURCES and look under MY PAST MEETINGS.
Delegates at a symposium held at the Royal Pharmaceutical Society